

## Lytix Biopharma: Invitation to Q3 2024 Results Presentation

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its third quarter 2024 financial results on Tuesday, 19 November 2024.

Join us for a live webcast presentation featuring **CEO Øystein Rekdal** and **CFO Gjest Breistein**, where they will discuss the results and provide key insights.

**Date:** Tuesday, 19 November 2024

**Time:** 10:30 AM CET

### **Q&A Session:**

We welcome your questions in advance. Please send them to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com), and they will be addressed during the Q&A session following the presentation.

### **Webcast Details:**

The presentation and Q&A session will be conducted in English. You can view the live event by registering here: [https://channel.royalcast.com/landingpage/hegnarmedia/20241119\\_7/](https://channel.royalcast.com/landingpage/hegnarmedia/20241119_7/)

### **Missed the Live Session?**

A recording of the presentation will be available shortly after the event on our financial reports page: <https://www.lytixbiopharma.com/financial-reports>

### **For more information, please contact:**

Gjest Breistein, CFO

+47 952 60 512

[gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)

### **About Lytix:**

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.